Equitable Representation of Pregnant and Lactating Women in Clinical Research: A Historical Review and Critical Analysis of Proposed Legislation

Abstract

A long history of policymaking and regulation constructed for the purpose of ensuring adequate fetal and infant protections has inadvertently sanctioned the widespread exclusion of pregnant and lactating patients from biomedical research, leaving a paucity of high quality data necessary for clinical decision-making. Although well-intended, the regulatory classification of pregnant women as “vulnerable,” in conjunction with burdensome enrollment criteria and other factors weighing against broad inclusion, have ultimately placed the health and safety of these women and their babies in jeopardy. Robust measures are urgently needed to overcome patient and physician reluctance, address substantial evidence gaps, and rectify long-standing disparities which precipitate disproportionately poor health outcomes among this population. In February 2023, the Advancing Safe Medications for Moms and Babies Act of 2023 (the Act) was introduced in the United States House of Representatives with the overarching goal of enabling pregnant and lactating women to achieve equitable participation in clinical research and contribute to developing important biomedical knowledge to guide and improve health care delivered to these patients. This review discusses the historical influence of federal human subject protection regulations on the health and clinical treatment of pregnant and lactating women, outlines and critically analyzes the provisions incorporated into the Act, and reflects on the potential long-term impact the Act would have should it be successful in becoming law.

Key Points

• Pregnant and lactating patients are widely excluded from clinical research.

• Evidence guiding the treatment of these patients is limited and of unacceptably low quality.

• Proposed legislation seeks to rectify disparities and empower these patients through improved representation in research.

Keywords

pregnancy - lactation - health policy - health equity - drug safety - clinical research - legislation

Publication History

Received: 30 November 2023

Accepted: 27 March 2024

Accepted Manuscript online:
17 April 2024

Article published online:
07 May 2024

• References

• 1 Wang J, Johnson T, Sahin L. et al. Evaluation of the safety of drugs and biological products used during lactation: workshop summary. Clin Pharmacol Ther 2017; 101 (06) 736-744
• 2 U.S. Centers for Disease Control and Prevention. Breastfeeding Rates. Breastfeeding Among U.S. Children Born 2013–2020. , CDC National Immunization Survey-Child. 2023 . Accessed October 13, 2023 at: https://www.cdc.gov/breastfeeding/data/nis_data/results.html
• 3 Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: final data for 2021. Natl Vital Stat Rep 2023; 72 (01) 1-53
• 4 Lyerly AD, Little MO, Faden R. The second wave: toward responsible inclusion of pregnant women in research. Int J Fem Approaches Bioeth 2008; 1 (02) 5-22
• 5 Nelson KM, Irvin-Choy N, Hoffman MK, Gleghorn JP, Day ES. Diseases and conditions that impact maternal and fetal health and the potential for nanomedicine therapies. Adv Drug Deliv Rev 2021; 170: 425-438
• 6 Sun D, Hutson JR, Garcia-Bournissen F. Drug therapy during pregnancy. Br J Clin Pharmacol 2022; 88 (10) 4247-4249
• 7 Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011; 157C [phone]
• 8 Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011; 205 (01) 51.e1-51.e8
• 9 Ayad M, Costantine MM. Epidemiology of medications use in pregnancy. Semin Perinatol 2015; 39 (07) 508-511
• 10 Riley LE, Cahill AG, Beigi R, Savich R, Saade G. Improving safe and effective use of drugs in pregnancy and lactation: workshop summary. Am J Perinatol 2017; 34 (08) 826-832
• 11 Haas DM, Marsh DJ, Dang DT. et al. Prescription and other medication use in pregnancy. Obstet Gynecol 2018; 131 (05) 789-798
• 12 Stultz EE, Stokes JL, Shaffer ML, Paul IM, Berlin CM. Extent of medication use in breastfeeding women. Breastfeed Med 2007; 2 (03) 145-151
• 13 de Waard M, Blomjous BS, Hol MLF. et al. Medication use during pregnancy and lactation in a Dutch population. J Hum Lact 2019; 35 (01) 154-164
• 14 U.S. Food and Drug Administration. Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials Guidance for Industry. 2018 . Accessed April 22, 2024 at: https://www.fda.gov/media/112195/download
• 15 Congress.gov. To implement certain recommendations to promote the inclusion of pregnant and lactating women in clinical research, and for other purposes. H.R. 1117. 118th Congress, 1st Session. February 21, 2023. Accessed August 29, 2023 at: https://www.congress.gov/bill/118th-congress/house-bill/1117
• 16 The National Research Act. Pub. L. 93–348 (July 12, 1974). Accessed October 12, 2023 at: https://www.govinfo.gov/content/pkg/STATUTE-88/pdf/STATUTE-88-Pg342.pdf
• 17 The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. April 18, 1979 . Accessed April 22, 2024 at: https://www.hhs.gov/ohrp/sites/default/files/the-belmont-report-508c_FINAL.pdf
• 18 Federal Policy for the Protection of Human Subjects. 56 Fed. Reg. 28003 (June 18, 1991 ). Accessed October 13, 2023 at: https://www.federalregister.gov/citation/56-FR-28003
• 19 U.S. Code of Federal Regulations. Title 45, Public Welfare. Last Amended November 22, 2023 . Accessed November 23, 2023 at: https://www.ecfr.gov/current/title-45
• 20 U.S. Code of Federal Regulations. Title 21, Food and Drugs. Last Amended November 21, 2023 . Accessed November 23, 2023 at: https://www.ecfr.gov/current/title-21
• 21 Meyer MN. There oughta be a law: when does(n't) the U.S. Common Rule apply?. J Law Med Ethics 2020; 48 (1_suppl): 60-73
• 22 Tovino SA. Mobile research applications and state research laws. J Law Med Ethics 2020; 48 (1_suppl): 82-86
• 23 Fetuses, Pregnant Women, In Vitro Fertilization. 40 Fed. Reg. 33526 (August 8, 1975 ). Accessed November 2, 2023 at: https://www.federalregister.gov/citation/40-FR-33526
• 24 U.S. Food and Drug Administration. Guidance for Industry: General Considerations for the Clinical Evaluation of Drugs. 1977 . Accessed April 22, 2024 at: https://www.fda.gov/media/71495/download
• 25 U.S. Centers for Disease Control and Prevention. CDC Procedures for Protection of Human Research Participants. October 1997 . Accessed April 22, 2024 at: https://stacks.cdc.gov/view/cdc/13304
• 26 U.S. Code of Federal Regulations. Title 45, Public Welfare. Pre-2018 Revision. October 1, 2016 . Accessed October 13, 2023 at: https://www.govinfo.gov/content/pkg/CFR-2016-title45-vol1/pdf/CFR-2016-title45-vol1-part46.pdf
• 27 U.S. Food and Drug Administration. Clinical Lactation Studies: Considerations for Study Design Guidance for Industry. May 2019 . Accessed April 22, 2024 at: https://www.fda.gov/media/124749/download
• 28 Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: issues in clinical research. Womens Health Issues 2013; 23 (01) e39-e45
• 29 Protection of Human Research Subjects. 63 Fed. Reg. 27797 (May 20, 1998 ). Accessed November 6, 2023 at: https://www.govinfo.gov/content/pkg/FR-1998-05-20/pdf/98-13091.pdf
• 30 Protection of Human Research Subjects. 66 Fed. Reg. 56778 (November 13, 2001 ). Accessed October 30, 2023 at: https://www.govinfo.gov/content/pkg/FR-2001-11-13/pdf/01-28440.pdf
• 31 Institute of Medicine (US) Committee on Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies. Mastroianni AC, Faden R, Federman D. eds. Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies. Washington (DC):: National Academies Press (US);; 1994
• 32 Macklin R. Enrolling pregnant women in biomedical research. Lancet 2010; 375 (9715) 632-633
• 33 van der Graaf R, van der Zande ISE, den Ruijter HM. et al. Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach. Trials 2018; 19 (01) 78
• 34 Susukida R, Crum RM, Ebnesajjad C, Stuart EA, Mojtabai R. Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network. Addiction 2017; 112 (07) 1210-1219
• 35 Hariton E, Locascio JJ. Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials. BJOG 2018; 125 (13) 1716
• 36 Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 2005; 365 (9453) 82-93
• 37 Task Force on Research Specific to Pregnant Women and Lactating Women. Report to Secretary, Health and Human Services Congress. Accessed April 22, 2024 at: https://www.nichd.nih.gov/sites/default/files/2018-09/PRGLAC_Report.pdf
• 38 U.S. Food and Drug Administration. Postapproval Pregnancy Safety Studies Guidance for Industry. May 2019 . Accessed April 22, 2024 at: https://www.fda.gov/media/124746/download
• 39 Byrne JJ, Saucedo AM, Spong CY. Evaluation of drug labels following the 2015 pregnancy and lactation labeling rule. JAMA Netw Open 2020; 3 (08) e2015094
• 40 Peters SL, Lind JN, Humphrey JR. et al. Safe lists for medications in pregnancy: inadequate evidence base and inconsistent guidance from Web-based information, 2011. Pharmacoepidemiol Drug Saf 2013; 22 (03) 324-328
• 41 Mulder B, Bijlsma MJ, Schuiling-Veninga CC. et al. Risks versus benefits of medication use during pregnancy: what do women perceive?. Patient Prefer Adherence 2017; 12: 1-8
• 42 Tefera YG, Gebresillassie BM, Getnet Mersha A, Belachew SA. Beliefs and risk awareness on medications among pregnant women attending the antenatal care unit in Ethiopia University Hospital. Overestimating the risks is another dread. Front Public Health 2020; 8: 28
• 43 21st Century Cures Act. . Pub. L. 114–255 (December 13, 2016). Accessed October 12, 2023 at: https://www.govinfo.gov/content/pkg/PLAW-114publ255/pdf/PLAW-114publ255.pdf
• 44 Congress.gov. To provide for the establishment of the Task Force on Research Specific to Pregnant Women and Lactating Women, to require an annual report to Congress on approved new drug applications with information on pregnancy and lactation, and for other purposes. H.R. 5219. 114th Congress, 2nd Session. May 12, 2016. Accessed October 23, 2023 at: https://www.congress.gov/bill/114th-congress/house-bill/5219/titles?r=95
• 45 Castor CUS. Representative Kathy Castor. Rep. Castor Reintroduces Bipartisan Legislation to Promote the Inclusion of Pregnant and Lactating Women in Clinical Research. Press Release. February 23, 2023 . Accessed November 15, 2023 at: https://castor.house.gov/news/documentsingle.aspx?DocumentID=404052
• 46 U.S. Department of Health and Human Services. Charter: Task Force on Research Specific to Pregnant Women and Lactating Women. March 8, 2017 . Accessed April 22, 2024 at: https://www.nichd.nih.gov/sites/default/files/2017-09/PRGLAC_Signed_Charter_201704.pdf
• 47 United States Congress. National Institutes of Health Revitalization Act of 1993. Pub. L. 103–43 (June 10, 1993). Accessed October 16, 2023 at: https://www.congress.gov/103/statute/STATUTE-107/STATUTE-107-Pg122.pdf
• 48 Pediatric Research Equity Act of 2003. Pub. L. 108–155 (December 3, 2003). Accessed November 9, 2023 at: https://www.govinfo.gov/content/pkg/PLAW-108publ155/pdf/PLAW-108publ155.pdf
• 49 Tahhan AS, Vaduganathan M, Greene SJ. et al. Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review. JAMA Cardiol 2018; 3 (10) 1011-1019
• 50 Khan MS, Shahid I, Siddiqi TJ. et al. Ten-year trends in enrollment of women and minorities in pivotal trials supporting recent US Food and Drug Administration approval of novel cardiometabolic drugs. J Am Heart Assoc 2020; 9 (11) e015594
• 51 Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am 2022; 11: 100252
• 52 Bourgeois FT, Kesselheim AS. Promoting pediatric drug research and labeling - outcomes of legislation. N Engl J Med 2019; 381 (09) 875-881
• 53 Hwang TJ, Orenstein L, Kesselheim AS, Bourgeois FT. Completion rate and reporting of mandatory pediatric postmarketing studies under the US Pediatric Research Equity Act. JAMA Pediatr 2019; 173 (01) 68-74
• 54 U.S. Government Accountability Office. Women's Health: Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement. GAO-01-754. 2001 . Accessed November 12, 2023 at: https://www.govinfo.gov/content/pkg/GAOREPORTS-GAO-01-754/pdf/GAOREPORTS-GAO-01-754.pdf
• 55 Tishler CL, Reiss NS. Pediatric drug-trial recruitment: enticement without coercion. Pediatrics 2011; 127 (05) 949-954
• 56 Mackenzie IS, Wei L, Rutherford D. et al. Promoting public awareness of randomised clinical trials using the media: the 'Get Randomised' campaign. Br J Clin Pharmacol 2010; 69 (02) 128-135
• 57 Getz KA. Impact of in-pharmacy education on patients' knowledge and attitudes about clinical trials. Ther Innov Regul Sci 2013; 47 (03) 336-340
• 58 Frew PM, Saint-Victor DS, Isaacs MB. et al. Recruitment and retention of pregnant women into clinical research trials: an overview of challenges, facilitators, and best practices. Clin Infect Dis 2014; 59 (suppl 7) S400-S407
• 59 Williams CP, Senft Everson N, Shelburne N, Norton WE. Demographic and health behavior factors associated with clinical trial invitation and participation in the United States. JAMA Netw Open 2021; 4 (09) e2127792
• 60 Protection of Human Subjects and Institutional Review Boards. 87 Fed. Reg. 58733 (September 28, 2022). Accessed November 13, 2023 at: https://www.govinfo.gov/content/pkg/FR-2022-09-28/pdf/2022-21088.pdf
• 61 Van Norman GA. Expanding patient access to investigational drugs: single patient investigational new drug and the “Right to Try”. JACC Basic Transl Sci 2018; 3 (02) 280-293
• 62 Fenerty SD, West C, Davis SA, Kaplan SG, Feldman SR. The effect of reminder systems on patients' adherence to treatment. Patient Prefer Adherence 2012; 6: 127-135
• 63 Matsui D. Adherence with drug therapy in pregnancy. Obstet Gynecol Int 2012; 2012: 796590
• 64 Wada K, Evans MK, de Vrijer B, Nisker J. Clinical research with pregnant women: perspectives of pregnant women, health care providers, and researchers. Qual Health Res 2018; 28 (13) 2033-2047
• 65 Bianchi DW, Clayton JA, Zenk SN. Addressing the public health crisis of maternal mortality: a national research agenda. JAMA 2023; 330 (18) 1729-1730
• 66 Han B, Compton WM, Einstein EB, Elder E, Volkow ND. Pregnancy and postpartum drug overdose deaths in the US before and during the COVID-19 pandemic. JAMA Psychiatry 2023; In press
• 67 Hoyert DL. Maternal mortality rates in the United States, 2021. NCHS Health E-Stats. Accessed November 20, 2023 at: https://www.cdc.gov/nchs/data/hestat/maternal-mortality/2021/maternal-mortality-rates-2021.pdf
• 68 Gelb ER, LeDuc M, Creason KS. Joint Letter to Reps. Castor, Underwood and Fitzpatrick Regarding the Advancing Safe Medications for Moms and Babies Act of 2023. June 27, 2023 . Accessed April 22, 2024 at: https://policysearch.wpengine.com/wp-content/uploads/AOA-and-ACOOG-Letter-of-Support-HR-1117-Advancing-Safe-Medications-for-Moms-and-Babies-Act-of-2023-Final.pdf
• 69 Frankel L, Herrera Beutler J, Roybal-Allard L. et al. Joint Letter to The Honorable Xavier Becerra Regarding the Task Force on Research Specific to Pregnant Women and Lactating Women. January 21, 2022 . Accessed April 22, 2024 at: https://frankel.house.gov/uploadedfiles/prglac_letter.pdf
• 70 Dobbs v. Jackson Women's Health Organization. 597 US __, 213 L. Ed. 2d 545. (2022).
• 71 Scheinerman N, Callahan KP. Legal discrepancies and expectations of women: abortion, fetal therapy, and NICU care. Hastings Cent Rep 2023; 53 (02) 36-43